Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor

Kidney International

Volumn 72, Issue 8, 2007, Pages 965-976

  Chuang, P Y ^a   Yu, Q ^a   Fang, W ^a   Uribarri, J ^a   He, J C ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Advanced glycation endproducts; Akt; Phosphorylation; RAGE; Transcription factor

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BOVINE SERUM ALBUMIN; COLLAGEN TYPE 4; FOXO4 TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CULTURE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN ISOLATION;

ANIMALS; APOPTOSIS; CELLS, CULTURED; CHRONIC DISEASE; FORKHEAD TRANSCRIPTION FACTORS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY DISEASES; MICE; NECROSIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PODOCYTES; REACTIVE OXYGEN SPECIES; RECEPTORS, IMMUNOLOGIC; RNA, SMALL INTERFERING; SERUM ALBUMIN; SIGNAL TRANSDUCTION;

EID: 34948906839     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002456     Document Type: Article

References (35)

1. USRDS: the United States Renal Data System. Am J Kidney Dis 2003; 43: 1-230.
2. Ziyadeh FN. Mediators of diabetic renal disease: the case for TGF-beta as the major mediator. J Am Soc Nephrol 2004; 15: S55-S57.
3. Wendt TM, Tanji N, Guo J et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162: 1123-1137.
4. Pagtalunan ME, Miller PL, Jumping-Eagle S et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 15: 342-348.
5. Drummond K, Mauer M. the early natural history of nephropathy in type 1 diabetes. II. Early renal structural changes in type 1 diabetes. Diabetes 2002; 51: 1580-1587.
6. Susztak K, Raff AC, Schiff M et al. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006; 55: 225-233.
7. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69: 2131-2147.
8. Vlassara H, Striker LJ, Teichberg S et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994; 91: 11704-11708.
9. Zheng F, He C, Cai W et al. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev 2002; 18: 224-237.
10. Soulis T, Cooper ME, Vranes D et al. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to duration of treatment. Kidney Int 1996; 50: 627-634.
11. Yamamoto Y, Kato I, Doi T et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001; 108: 261-268.
12. Neeper M, Schmidt AM, Brett J et al. Cloning and expression of RAGE: a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267: 14998-15004.
13. Schmidt AM, Vianna M, Gerlach M et al. Isolation and characterization of binding proteins for advanced glycosylation endproducts from lung tissue which are present on the endothelial cell surface. J Biol Chem 1992; 267: 14987-14997.
14. Ehlermann P, Eggers K, Bierhaus A et al. Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabeto 2006; 5: 6.
15. Yan SD, Schmidt AM, Anderson GM et al. Enhanced cellular oxidant stress by the interaction of advanced glycation endproducts with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-9897.
16. Lander HL, Tauras JM, Ogiste JS et al. Activation of the receptor for advanced glycation endproducts triggers a MAP kinase pathway regulated by oxidant stress. J Biol Chem 1997; 272: 17810-17814.
17. Wautier MP, Chappey O, Corda S et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280: E685-E694.
18. Cai W, He JC, Zhu L et al. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci USA 2006; 103: 13801-13806.
19. Drummond KN, Kramer MS, Suissa S et al. International Diabetic Nephropathy Study Group. Effects of duration and age at onset of type 1 diabetes on preclinical manifestations of nephropathy. Diabetes 2003; 52: 1818-1824.
20. Alikhani M, Maclellan C, Raptis M et al. Advanced glycation endproducts induce apoptosis in fibroblasts through activation of ROS MAP kinases and FOXO1 transcription factor. Am J Physiol Cell Physiol 2007; 292: C850-C856.
21. Kikuchi S, Shinpo K, Moriwaka F et al. Neurotoxicity of methylglyoxal and 3-deoxyglucosone on cultured cortical neurons: synergism between glycation and oxidative stress, possibly involved in neurodegenerative diseases. J Neurosci Res 1999; 57: 280-289.
22. Accili D, Arden K. FoxOs at the crossroads of cellular metabolism, differentiation, transformation. Cell 2004; 117: 421-426.
23. Koshikawa M, Mukoyama M, Mori K et al. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol 2005; 16: 2690-2701.
24. Dijkers PF, Birkenkamp KU, Lam EW et al. FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J Cell Biol 2002; 156: 531-542.
25. Alikhani M, Alikhani Z, Boyd C et al. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 2007; 40: 345-353.
26. Pedchenko VK, Chetyrkin SV, Chuang P et al. Mechanism of perturbation of integrin-mediated cell-matrix interactions by reactive carbonyl compounds and its implication for pathogenesis of diabetic nephropathy. Diabetes 2005; 54: 2952-2960.
27. Huber TB, Hartleben B, Kim J et al. Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate Akt-dependent signaling. Mol Cell Biol 2003; 23: 4917-4928.
28. Doublier S, Salvidio G, Lupia E et al. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003; 52: 1023-1030.
29. Furukawa-Hibi Y, Kobayashi Y, Chen C et al. FOXO transcription factors in cell-cycle regulation and the response to oxidative stress. Antiox Redox Signaling 2005; 7: 752-760.
30. Kops GJ, Burgering BM. Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J Mol Med 1999; 77: 656-665.
31. Brunet A, Sweeney LB, Sturgill JF et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303: 2011-2015.
32. Smith WW, Norton DD, Gorospe M et al. Phosphorylation of p66Shc and forkhead proteins mediates A-beta toxicity. J Cell Biol 2005; 169: 331-339.
33. Mitsuhashi T, Li YM, Fishbane S et al. Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix. J Clin Invest 1997; 100: 847-854.
34. Makita Z, Vlassar A, Cerami A et al. Immunochemical detection of advanced glycation end products in vivo. J Biol Chem 1992; 267: 5133-5138.
35. -ΔΔCt method. Methods 2001; 25: 402-408.